Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1994 2
1995 1
1998 1
1999 2
2000 4
2001 2
2002 2
2003 2
2004 1
2005 1
2006 4
2007 8
2008 5
2009 6
2010 7
2011 2
2012 5
2013 9
2014 11
2015 11
2016 6
2017 5
2019 8
2020 9
2021 7
2022 8
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed (Bookshelf cited) for id: 418825

118 results

Results by year

Filters applied: . Clear all
Page 1
Functional outcome after pediatric cerebral cavernous malformation surgery.
Rauschenbach L, Santos AN, Dinger TF, Darkwah Oppong M, Li Y, Tippelt S, Dohna-Schwake C, Schmidt B, Jabbarli R, Wrede KH, Sure U, Dammann P. Rauschenbach L, et al. Sci Rep. 2023 Feb 9;13(1):2286. doi: 10.1038/s41598-023-29472-5. Sci Rep. 2023. PMID: 36759693 Free PMC article.
Intracranial Hemorrhage Rate and Lesion Burden in Patients With Familial Cerebral Cavernous Malformation.
Weinsheimer S, Nelson J, Abla AA, Ko NU, Tsang C, Okoye O, Zabramski JM, Akers A, Zafar A, Mabray MC, Hart BL, Morrison L, McCulloch CE, Kim H; Brain Vascular Malformation Consortium Cerebral Cavernous Malformation Investigator Group *. Weinsheimer S, et al. J Am Heart Assoc. 2023 Feb 7;12(3):e027572. doi: 10.1161/JAHA.122.027572. Epub 2023 Jan 25. J Am Heart Assoc. 2023. PMID: 36695309 Free PMC article.
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
Lanfranconi S, Scola E, Meessen JMTA, Pallini R, Bertani GA, Al-Shahi Salman R, Dejana E, Latini R; Treat_CCM Investigators. Lanfranconi S, et al. Lancet Neurol. 2023 Jan;22(1):35-44. doi: 10.1016/S1474-4422(22)00409-4. Epub 2022 Nov 17. Lancet Neurol. 2023. PMID: 36403580 Free article. Clinical Trial.
118 results